pumitamig + gemcitabine + carboplatin

This is a **combination therapy** consisting of **pumitamig**, **gemcitabine**, and **carboplatin**. - Gemcitabine is a **nucleoside analog** used as a chemotherapy agent that inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. - Carboplatin is a **platinum-based chemotherapeutic agent** that creates DNA crosslinks, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells. - Pumitamig appears to be an investigational or newly introduced agent, but no mechanism, developer, or approved details could be found in current authoritative sources, suggesting it may be a code name or a compound not widely described in literature as of the search date. - The gemcitabine and carboplatin combination is commonly used for several cancer types, including **advanced non-small-cell lung cancer, bladder carcinoma, and metastatic breast cancer**, particularly in patients who cannot tolerate cisplatin due to toxicity or comorbidities[1][2][3][4][5]. - All three agents are typically administered intravenously by infusion.

Other names

GemCarbo